Q12809 |
KCNH2_HUMAN |
Heart failure [ICD-11: BD10-BD1Z] |
Q12809 |
KCNH2_HUMAN |
Sleep-wake disorder [ICD-11: 7A00-7B2Z] |
Q12809 |
KCNH2_HUMAN |
Malaria [ICD-11: 1F40-1F45] |
Q12809 |
KCNH2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
Q12809 |
KCNH2_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
Q12809 |
KCNH2_HUMAN |
Cardiac arrhythmia [ICD-11: BC9Z] |
Q12809 |
KCNH2_HUMAN |
Angina pectoris [ICD-11: BA40] |
Q12809 |
KCNH2_HUMAN |
Genetic cardiac arrhythmia [ICD-11: BC65] |
Q12809 |
KCNH2_HUMAN |
Ovarian cancer [ICD-11: 2C73] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
P06276 |
CHLE_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P06276 |
CHLE_HUMAN |
Tonus and reflex abnormality [ICD-11: MB47] |
P06276 |
CHLE_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P06276 |
CHLE_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P06276 |
CHLE_HUMAN |
Eexposure to noxious substances harmful effect [ICD-11: NE61] |
P06276 |
CHLE_HUMAN |
Toxicity [ICD-11: N.A.] |
P06276 |
CHLE_HUMAN |
Unspecific substance harmful effect [ICD-11: NE6Z] |
P10275 |
ANDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P10275 |
ANDR_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10275 |
ANDR_HUMAN |
Alcoholic liver disease [ICD-11: DB94] |
P10275 |
ANDR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 |
ANDR_HUMAN |
Cardiovascular disease [ICD-11: BA00-BE2Z] |
P10275 |
ANDR_HUMAN |
Chronic obstructive pulmonary disease [ICD-11: CA22] |
P10275 |
ANDR_HUMAN |
Female pelvic pain [ICD-11: GA34] |
P10275 |
ANDR_HUMAN |
Hypo-osmolality/hyponatraemia [ICD-11: 5C72] |
P10275 |
ANDR_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P10275 |
ANDR_HUMAN |
Mammary tumour [ICD-11: 2C60-2C6Z] |
P10275 |
ANDR_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P10275 |
ANDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10275 |
ANDR_HUMAN |
Testicular dysfunction [ICD-11: 5A81] |
P10275 |
ANDR_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P10275 |
ANDR_HUMAN |
Alopecia [ICD-11: ED70] |
P10275 |
ANDR_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P10275 |
ANDR_HUMAN |
Thrombosis [ICD-11: DB61-GB90] |
P10275 |
ANDR_HUMAN |
Contraceptive management [ICD-11: QA21] |
P10275 |
ANDR_HUMAN |
Heart failure [ICD-11: BD10-BD1Z] |
P10275 |
ANDR_HUMAN |
Muscle disorder [ICD-11: FB32-FB3Z] |
P10275 |
ANDR_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P10275 |
ANDR_HUMAN |
Cystic fibrosis [ICD-11: CA25] |
P10275 |
ANDR_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P10275 |
ANDR_HUMAN |
Cachexia [ICD-11: MG20] |
P10275 |
ANDR_HUMAN |
Dissociative neurological symptom disorder [ICD-11: 6B60] |
P10275 |
ANDR_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P10275 |
ANDR_HUMAN |
Oesophagitis [ICD-11: DA24] |
P10275 |
ANDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10275 |
ANDR_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P10275 |
ANDR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 |
ANDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10275 |
ANDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P10275 |
ANDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P84022 |
SMAD3_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
P84022 |
SMAD3_HUMAN |
Kidney fibrosis [ICD-11: GC01] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P19838 |
NFKB1_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P19838 |
NFKB1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P19838 |
NFKB1_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P11511 |
CP19A_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P11511 |
CP19A_HUMAN |
Cushing syndrome [ICD-11: 5A70] |
P11511 |
CP19A_HUMAN |
Oesophagitis [ICD-11: DA24] |
P11511 |
CP19A_HUMAN |
Endometriosis [ICD-11: GA10] |
P11511 |
CP19A_HUMAN |
Neuropathy [ICD-11: 8C0Z] |
P11511 |
CP19A_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P11511 |
CP19A_HUMAN |
Prostate disease [ICD-11: GA91] |
Q13148 |
TADBP_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q13148 |
TADBP_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P03372 |
ESR1_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P03372 |
ESR1_HUMAN |
Acquired prion disease [ICD-11: 8E01] |
P03372 |
ESR1_HUMAN |
Adrenal cancer [ICD-11: 2D11] |
P03372 |
ESR1_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P03372 |
ESR1_HUMAN |
Contraceptive management [ICD-11: QA21] |
P03372 |
ESR1_HUMAN |
Dyspareunia [ICD-11: GA12] |
P03372 |
ESR1_HUMAN |
Female infertility [ICD-11: GA31] |
P03372 |
ESR1_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P03372 |
ESR1_HUMAN |
Male infertility [ICD-11: GB04] |
P03372 |
ESR1_HUMAN |
Menopausal disorder [ICD-11: GA30] |
P03372 |
ESR1_HUMAN |
Menstrual cycle bleeding disorder [ICD-11: GA20] |
P03372 |
ESR1_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P03372 |
ESR1_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P03372 |
ESR1_HUMAN |
Skeletal anomaly [ICD-11: LD24] |
P03372 |
ESR1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P03372 |
ESR1_HUMAN |
Vaginitis [ICD-11: GA02] |
P03372 |
ESR1_HUMAN |
Virus infection [ICD-11: 1A24-1D9Z] |
P03372 |
ESR1_HUMAN |
Endometriosis [ICD-11: GA10] |
P03372 |
ESR1_HUMAN |
Female genital tract noninflammatory disorder [ICD-11: GA1Y] |
P03372 |
ESR1_HUMAN |
Female pelvic pain [ICD-11: GA34] |
P03372 |
ESR1_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
P03372 |
ESR1_HUMAN |
Breast in situ carcinoma [ICD-11: 2E65] |
P03372 |
ESR1_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P03372 |
ESR1_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P03372 |
ESR1_HUMAN |
Brain cancer [ICD-11: 2A00] |
P03372 |
ESR1_HUMAN |
Metastatic tumour [ICD-11: 2D50-2E2Z] |
P03372 |
ESR1_HUMAN |
Irregularities [ICD-11: N.A.] |
P03372 |
ESR1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
P03372 |
ESR1_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P03372 |
ESR1_HUMAN |
Eye disorder [ICD-11: 9A01-9A0Z] |
P03372 |
ESR1_HUMAN |
Dissociative neurological symptom disorder [ICD-11: 6B60] |
P03372 |
ESR1_HUMAN |
Thrombocytopenia [ICD-11: 3B64] |
P03372 |
ESR1_HUMAN |
Atrophy [ICD-11: 9A2Y-9C40] |
P03372 |
ESR1_HUMAN |
Joint pain [ICD-11: ME82] |
P03372 |
ESR1_HUMAN |
Sexual dysfunction [ICD-11: HA00-HA01] |
P03372 |
ESR1_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P04150 |
GCR_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P04150 |
GCR_HUMAN |
Indeterminate colitis [ICD-11: DD72] |
P04150 |
GCR_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P04150 |
GCR_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P04150 |
GCR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P04150 |
GCR_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P04150 |
GCR_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 |
GCR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 |
GCR_HUMAN |
Adaptive immunity immunodeficiency [ICD-11: 4A01] |
P04150 |
GCR_HUMAN |
Adrenogenital disorder [ICD-11: 5A71] |
P04150 |
GCR_HUMAN |
Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P04150 |
GCR_HUMAN |
Asthma [ICD-11: CA23] |
P04150 |
GCR_HUMAN |
Atopic eczema [ICD-11: EA80] |
P04150 |
GCR_HUMAN |
Chronic obstructive pulmonary disease [ICD-11: CA22] |
P04150 |
GCR_HUMAN |
Cushing syndrome [ICD-11: 5A70] |
P04150 |
GCR_HUMAN |
Eczema [ICD-11: EA80-EA89] |
P04150 |
GCR_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P04150 |
GCR_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P04150 |
GCR_HUMAN |
Oesophagitis [ICD-11: DA24] |
P04150 |
GCR_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P04150 |
GCR_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P04150 |
GCR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P04150 |
GCR_HUMAN |
Spine/trunk injury [ICD-11: ND51] |
P04150 |
GCR_HUMAN |
Vasomotor/allergic rhinitis [ICD-11: CA08] |
P04150 |
GCR_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
P04150 |
GCR_HUMAN |
Otitis externa [ICD-11: AA00-AA13] |
P04150 |
GCR_HUMAN |
Substance abuse [ICD-11: 6C40] |
P04150 |
GCR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P04150 |
GCR_HUMAN |
Depression [ICD-11: 6A70-6A7Z] |
P04150 |
GCR_HUMAN |
Mood disorder [ICD-11: 6A60-6E23] |
P04150 |
GCR_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P04150 |
GCR_HUMAN |
Vitamin deficiency [ICD-11: 5B55-5B5F] |
P04150 |
GCR_HUMAN |
Retinopathy [ICD-11: 9B71] |
P04150 |
GCR_HUMAN |
Anxiety disorder [ICD-11: 6B00-6B0Z] |
P28482 |
MK01_HUMAN |
Melanoma [ICD-11: 2C30] |
P28482 |
MK01_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P28482 |
MK01_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P28482 |
MK01_HUMAN |
Arteries/arterioles disorder [ICD-11: BD52] |
P28482 |
MK01_HUMAN |
Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] |
P28482 |
MK01_HUMAN |
Transplant rejection [ICD-11: NE84] |
P28482 |
MK01_HUMAN |
Mature T-cell lymphoma [ICD-11: 2A90] |
P28482 |
MK01_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
Q03181 |
PPARD_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q03181 |
PPARD_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
Q03181 |
PPARD_HUMAN |
Autoimmune liver disease [ICD-11: DB96] |
Q03181 |
PPARD_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q03181 |
PPARD_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
Q03181 |
PPARD_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
Q03181 |
PPARD_HUMAN |
Dyslipidemia [ICD-11: 5C80-5C81] |
Q03181 |
PPARD_HUMAN |
Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q03181 |
PPARD_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
Q03181 |
PPARD_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P19793 |
RXRA_HUMAN |
Kaposi sarcoma [ICD-11: 2B57] |
P19793 |
RXRA_HUMAN |
Mycosis fungoides [ICD-11: 2B01] |
P16473 |
TSHR_HUMAN |
Hypo-thyroidism [ICD-11: 5A00] |
P16473 |
TSHR_HUMAN |
Thyroid cancer [ICD-11: 2D10] |
P10145 |
IL8_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P10145 |
IL8_HUMAN |
COVID-19 [ICD-11: 1D6Y] |
P10145 |
IL8_HUMAN |
Melanoma [ICD-11: 2C30] |
P10145 |
IL8_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10145 |
IL8_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P51449 |
RORG_HUMAN |
Autoimmune disease [ICD-11: 4A40-4A45] |
P51449 |
RORG_HUMAN |
Lung cancer [ICD-11: 2C25] |
P51449 |
RORG_HUMAN |
Psoriasis [ICD-11: EA90] |
P51449 |
RORG_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P51449 |
RORG_HUMAN |
Crohn disease [ICD-11: DD70] |
P51449 |
RORG_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P51449 |
RORG_HUMAN |
Arterial occlusive disease [ICD-11: BD40] |
P51449 |
RORG_HUMAN |
Liver cancer [ICD-11: 2C12] |
P51449 |
RORG_HUMAN |
Rheumatoid arthritis [ICD-11: FA20] |
P08185 |
CBG_HUMAN |
Asthma [ICD-11: CA23] |
P08185 |
CBG_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P08185 |
CBG_HUMAN |
Respiratory system disease [ICD-11: CB40-CB7Z] |
P08185 |
CBG_HUMAN |
Retinopathy [ICD-11: 9B71] |
P05804 |
BGLR_ECOLI |
Therapeutic intestinal toxicity [ICD-11: DA94] |
P18405 |
S5A1_HUMAN |
Prostate disease [ICD-11: GA91] |
P18405 |
S5A1_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P31213 |
S5A2_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P42330 |
AK1C3_HUMAN |
Female pelvic pain [ICD-11: GA34] |
P42330 |
AK1C3_HUMAN |
Prostate cancer [ICD-11: 2C82] |